IPG 2017 net income drops; Bristol-Myers Squibb inks $1.85 billion deal with Nektar on cancer drug; Merck halts final-stage Alzheimer's drug.
Daniel Carucci is joining the Interpublic Group firm full-time after serving as a consultant and in roles with the U.N. Foundation and the U.S. Navy.
The company is also looking to better combine its web and social media presence.
Zimprich joins from Honeywell, where he led global business communications.
Amazon moves into medical supply market; Big Pharma gets a tax cut; Former Celgene CEO plans Senate run.
There was so much bigger-picture coverage of pharma and healthcare in 2017 - pricing, Affordable Care Act reform and repeal - that it was easy to lose sight of everything else. PwC's Health Research Institute has used its annual look-ahead report to spotlight a handful of undercover trends.
The pharma company manufactures the well-known opioid OxyContin.
Healthcare providers may understand its importance, but across the board not many are ready to meet the requirements of the program QPP, according to a study.
As the evidence mounts that high-deductibles don't cause patients to shop or save for healthcare, payers are taking note.
White House limits guidance documents; Top executives exit Axovant; Carroll nominated as drug czar.
More has been written about millennials — and their healthcare habits — than about any other generation. Here, Gen Y marketers explain why most of what you've read is wrong.
Study: Two prostate cancer drugs delay metastasis by two years; Budget deal funds CHIP for four years; Azar outlines Trump's drug pricing plans.
PhRMA wants to clear the air about drug pricing with the consumer-focused extension of the Let's Talk About Cost campaign.
Critics said the initial spots unnecessarily blamed IBD sufferers.
FDA approval of Gilead HIV drug prompts ViiV patent suit; Poll shows split in voter reaction to Trump opioid plan; Outcome Health partners with CDC.
Zero people have such tales about Robert Leverte, which is why news of his pending induction into the Medical Advertising Hall of Fame was received warmly when it was made public last October.
We asked some of the agency world's sharpest data people to answer a pair of questions about the future of data in and around pharma marketing. Here's what they had to say.
Study casts doubt on employee wellness programs; FDA identifies kratom as an opioid; House passes bill to modify ACA restaurant menu rules.
In the past, pharma hasn't used data effectively to engage its A-list HCPs. Five companies hope to change that.
LiquidHub formed a health- and life-sciences-focused offering last June after acquiring Eveo.
Burcin, who joins from Klick Health, is the former Global CEO of Havas Health.
The agency M&A market is changing as the big ad groups have been "distracted" by internal restructuring and new acquirers are emerging.
Allergan Q4 earnings beat estimates; Mars publishes research policies; Conway takes control of White House opioid agenda.
Snow Companies, which emphasizes patient storytelling, was founded by Brenda Snow in 2001.
McCann Worldwide has sent a memo to staff to encourage them to speak up if they face a 'behaviour or concern' in the workplace.
Opdivo hits key goal in late-stage trial; Philippines government sues Sanofi over anti-dengue vaccine; hospitals reach capacity amid record flu season.
Fueled by system-wide demand and facilitated by AI, the industry's lofty expectations around real-world evidence could soon be fulfilled
This year, the Super Bowl and World Cancer Day fall on the same date.
AstraZeneca strikes deals with Alibaba, Tencent; NY AG sues opioid maker; Justice Department wants more info on CVS-Aetna deal.
Spark has priced its cure for a rare form of blindness at $425,000 per eye. But rather than the science or the cost, pharma is buzzing over the company's outcomes-based pricing model
Amazon's ability to attract other employers makes its healthcare coalition very formidable, experts say
Details are vague, but the e-commerce giant indicated it's serious about getting into healthcare.
The network also appointed her predecessor, Nick Colucci, as COO of Publicis Communications North America, effective immediately.
Childs has worked at the network news division for more than a decade.
Vertex moves two cystic fibrosis drugs into Phase III trials; American Heart Association says breast cancer survivors have higher risk of cardiovascular disease; Blood test to predict Alzheimer's shows promise.
Glaze worked in Edelman's market access practice for more than seven years.
Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.
The nonprofit worked with creative agency E/LA on the push.
Four data aces share their backgrounds, inspirations, and guiding philosophies
CDC chief resigns; Amazon healthcare entry raises data concerns; Trump promises to make lower drug prices 'a priority'
Burson-Marsteller has appointed MSLGroup's EMEA head of healthcare to lead its own health practice in the UK, PRWeek has learned.
Jardiance treats patients with type 2 diabetes and heart disease, lowering blood sugar and reducing the risk of death from heart disease.
Amazon, Berkshire Hathaway, and JPMorgan team up to form a healthcare company; Takeda's Zika vaccine receives FDA fast-track status
Publicis Groupe has announced it has selected Microsoft has the technology partner to deliver its artificial intelligence platform Marcel.
Alan Maine has joined Edelman as a senior director in its London health team.
Outcome Health settles fraud allegations, reassigns leaders; Approval of generics surges during first year of Trump administration; Sanofi acquires coveted biotech firm.
WPP was brought on to help with consumer education about the food industry.
For some pharma brands, the price tag is just too high. For others, the platform isn't serious enough.
Read the January 2018 issue in its entirety.
Pharma groups upped lobbying spend in 2017; Novartis, Bayer heads dine with Trump at Davos; Illumina wins jury verdict against Roche subsidiary
Fidelino served on the Health & Wellness jury in 2015 and the Pharma jury last year. Levy has been a member of both Health category juries and was a speaker at the first Health Lions in 2014.
Somatix is a digital health platform that tracks movements through smartwatches.
Senate confirms Azar as HHS head; Spark licenses Luxturna to Novartis outside the U.S.; Glaxo and J&J top index of superbug combatants
Warc anticipates global adspend growth this year to ring in at a healthy 4.7%, or $572bn (£410bn).
WPP has become embroiled in a row over sexism and misogyny following an exposé into the lewd behaviour of a men-only event sponsored by the advertising giant in London.
Novartis sees single-digit growth with new CEO; J&J takes $13.6b charge in the wake of the new tax law; New York City invests in biotech
Clayman says the company's next 18 months are all about Zilretta, with further pipeline construction next up.
FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW
Not only isn't print dead, as ahead-of-themselves media wonks have claimed for the past decade, but it's thriving in a most unlikely environment: the point of care
Some microinfluencers see the latest YouTube guidelines as a "slap in the face."
Nick Law, the global chief creative officer of R/GA, is leaving the company after 17 years to take on the newly created role of chief creative officer across Publicis Groupe and president of Publicis Communications.
Sanofi to buy Bioverativ for $11.6 billion; Celgene to acquire Juno for $9 billion; Teva to lay off more than 200 in Philadelphia
She is overseeing three of the network's agencies in the newly created role.
Advertisers have until July to get their mobile pages up to speed.
Biogen, UCB reportedly showing interest in Acorda acquisition; Kite Pharma and Pfizer to develop combo lymphoma therapy; hospitals to form generics nonprofit
Senate committee votes in favor of Azar as new HHS head; FDA and DoD launch breakthrough designation program; Walmart offers free opioid disposal solution
The CEO of the independent healthcare agency discusses growing a business in digital in the early 2000s and the perks of remaining independent.
In an effort to assure advertisers and agencies on brand safety, Google has announced two new requirements for video creators that intend to join the YouTube Partner Program.
Celgene reportedly in talks to buy Juno; Novartis' Kymriah receives fast-track reviews in U.S. and Europe; BI's Gilotrif gets expanded approval in lung cancer
Although if approved, it's not likely to launch in the U.S. for quite some time.
Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn't overwhelm trial organizers.
Sigurdsson is charged with leading the agency's digital offering to meet growing client demand.
Merck's Keytruda combo therapy succeeds in Phase-III lung cancer trial; FDA launches pilot to address trial transparency; Spark's Luxturna overpriced, ICER says
New research calls into question the behavioral effects of some digital health tools.
Facebook's decision to reprioritise its news feed to favour "social interactions" over other forms of content may please its users but will be challenging for brands.
Pharma looks to Spark for pricing blueprint; Ipsen hires Amgen exec as CEO of North America; FDA could improve social-media approach, study finds
The founder of Stagwell has claimed digital marketing agencies are undervalued because investors still fail to appreciate how much digital communications and e-commerce are going to transform the economy.
Once Attorney General Jeff Sessions reversed the Cole memo, NORML began applying pressure both locally and nationally for changes in marijuana laws.
Collecting and analyzing data is a contentious question. High-profile data mavens offered some possible answers yesterday at the JP Morgan Healthcare Conference.
Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
For all the talk about new and better ways to engage, pharma still hasn't created an appreciably higher volume of satisfied — or informed — customers.
A plea for IT interoperability and a stinging criticism of the pharma industry over its lack of diversity were two highlights of yesterday's events.
Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict
In the absence of behemoths such as Facebook and Twitter, pharma is partnering with China's tech giants to snare a slice of a more than $100 billion market
How drugmakers should prepare for and respond to the forces poised to reshape the industry was a popular topic on day one of the 36th annual JP Morgan Healthcare Conference.
Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018
MM&M is calling for nominations for the 2018 class of Top 40 Healthcare Transformers and is seeking industry input for the Top 10 Innovation Catalysts.
Accenture will not consider a takeover bid for a large ad agency group because its chief executive says there has been a "100%" failure rate with such deals.
WPP has named Karen Blackett as its first UK country manager, making her the most important agency leader in the British ad industry.
Celgene to buy Impact Biomedicines for up to $7 billion; Pfizer plans to cut 300 positions in neuroscience; Perrigo hires new CEO
As HCPs continue to be stretched for time to diagnose and interact with patients, health bots could help reduce HCP workload and drive patient engagement.
Do the healthcare and pharma arms of Accenture, Deloitte, PwC, and other consultancies pose an existential threat to traditional healthcare agencies?
Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise
Kevin Griffis brought his experience in government and politics to Planned Parenthood at the perfect time, leading the fight to protect birth control coverage under the Trump administration and destigmatizing abortion.
US bank JPMorgan Chase has returned to advertising on YouTube only after developing its own algorithm that ensures its ads are not placed around questionable content.
Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy
Utah Senator who backed Orphan Drug Act will not seek reelection; medicines more expensive in 2018; Spark's genetic therapy for rare blindness costs $850,000
The group's reports, received with great interest by insurers and the Department of Veteran Affairs, have concluded certain high-profile drugs aren't worth the cost. Pharma still hasn't decided whether ICER is friend or foe.
A sea change may be afoot in OTC, with multiple healthcare businesses in play. Could consumer goods companies fill the void left by big pharma?
FDA approvals hit a 21-year high; drug prices account for higher U.S. healthcare spend; industry enters 2018 amidst consolidation, uncertainty
Study: male docs earn more than female peers; new Michigan law tackles opioid crisis; study: some docs billed Medicare for most expensive patient visit type